Acalabrutinib

Acalabrutinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Recurrent Chronic Lymphocytic Leukemia、Recurrent Small Lymphocytic Lymphoma、Refractory Chronic Lymphocytic Leukemia、Refractory Small Lymphocytic Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Acalabrutinib 研究

• Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  II 期招募中美国NCT03516617

• A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  III 期招募中美国澳大利亚比利时BrazilNCT06136559

• A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

  III 期招募中中国NCT07377578

• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  III 期招募中美国澳大利亚法国GreeceNCT06428019

• A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

  I 期 / II 期招募中美国Brazil德国PolandNCT03571568

• PICAROS - Acalabrutinib RWE on 1L CLL in Spain

  不适用招募中西班牙NCT05999877

• SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

  不适用招募中荷兰NCT07021495

• Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

  不适用招募中英国NCT05557695

• A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

  III 期招募中中国NCT06319456

• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  II 期招募中美国NCT04002947

• Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  II 期招募中美国NCT06757647

• AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database

  不适用招募中法国NCT06548152

• Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

  II 期招募中中国NCT06958705

• Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

  II 期 / III 期招募中丹麦荷兰瑞典NCT03868722

• Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

  不适用招募中法国NCT07174141

• Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

  I 期招募中美国澳大利亚NCT03666000

• Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

  II 期招募中美国NCT04404088

• Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

  II 期招募中美国NCT04941716

• Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

  III 期招募中德国NCT05820841

• Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus

  不适用招募中BelarusNCT07288515

• Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

  I 期 / II 期招募中美国澳大利亚比利时CzechiaNCT04502394

• Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

  I 期招募中美国NCT05943496

• Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

  不适用招募中美国NCT05643235

• Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

  II 期招募中美国NCT06054776

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。